Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition). William Gregory
target="_blank" rel="nofollow" href="#litres_trial_promo"> Comments
Part I: Product(s) Overview (GVP V. B.4)
Part II: Safety Specification (GVP V.B.5)
Part III: PV Plan, Including Post-authorization Safety Studies (GVP V.B.6 RMP part III)
Part IV: Plans for Post-authorization Efficacy Studies (GVP V.B.7 RMP part IV)
Part VI: Summary of the RMP (GVP V.B.9 RMP part VI)
Practicalities, Co-ordination, and Other Comments
Risk Management within Pharma Companies
Chapter 29Data Monitoring Committees and Investigational Review Boards/Ethics Committees
Data Monitoring Committees
Investigational Review Boards/Ethics Committees
Chapter 30Pharmaceutical Companies
Contract/Clinical Research Organizations
Mergers, Acquisitions, and Bankruptcies
Chapter 31Organization of a Typical Drug Safety Department
Qualified (Responsible) Person for Pharmacovigilance
Case Assessment and Prioritization
Signaling, Pharmacovigilance, Pharmacoepidemiology, Medical Information or Medical Affairs Unit
Labeling Review and Update for Safety
Information Technology/Informatics Liaison
Quality Documents Creation and Maintenance
Safety (AE) Exchange Agreement Function: Creation and Maintenance
Planning and Project Management/Operations